Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Net revenues	$ 351,318	$ 248,069	$ 177,026
Cost of revenues	88,606	80,048	55,610
Gross profit	262,712	168,021	121,417
Operating costs and expenses:
Research, development and clinical trials	79,003	50,574	38,103
Sales and marketing	96,675	77,663	63,528
General and administrative	87,948	73,456	59,114
Total operating costs and expenses	263,626	201,693	160,745
Operating income (loss)	(914)	(33,672)	(39,328)
Financial expenses (income), net	7,910	12,270	9,169
Income (loss) before income taxes	(8,824)	(45,942)	(48,497)
Income tax	(1,594)	17,617	13,165
Net income (loss)	$ (7,230)	$ (63,559)	$ (61,662)
Basic and diluted net income (loss) per ordinary share (in usd per share)	$ (0.07)	$ (0.69)	$ (0.70)
Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share (in shares)	97,237,549	91,828,043	88,546,719